China’s National Medical Products Administration (NMPA) and National Healthcare Security Administration (NHSA) formed a joint inspection team to screen drugs traceability-code clues and inspect medical institutions and pharmaceuticals wholesalers in

2026-07-13

China’s National Medical Products Administration (NMPA) and National Healthcare Security Administration (NHSA) formed a joint inspection team to screen drugs traceability-code clues and inspect medical institutions and pharmaceuticals wholesalers in selected cities in Inner Mongolia and Shanxi. The inspections focus on prominent medical-insurance fund management issues and key links in drug distribution, using drug traceability anomalies and clues of duplicate medical-insurance claims as entry points. Agencies inspected certain hospitals and pharmacies and said discovered violations will be strictly dealt with according to law.